Australian recommendations for the influenza vaccine composition for the 1999 season

This article published in Communicable Diseases Intelligence Volume 22, No 12, 26 November 1998 contains a report on the meeting of the Australian Influenza Vaccine Committee on Influenza Vaccines was convened on 7 October 1998.

Page last updated: 09 December 1998

A print friendly PDF version is available from this Communicable Diseases Intelligence issue's table of contents.


The meeting of the Australian Influenza Vaccine Committee (AIVC) on Influenza Vaccines was convened on 7 October 1998, in order to select virus strains for the manufacture of Influenza Vaccine for 1999 Season.

Having considered the information on international surveillance by WHO and up-to-date epidemiology and strains characterisation presented at the meeting the Committee considered that the WHO recommendations on the composition of vaccines for 1999 Season should be followed:
  • A (H3N2) an A/Sydney/5/97 (H3N2)-like strain, 15 g HA per dose.
  • A (H1N1) an A/Beijing/262/95 (H1N1)-like strain, 15 g HA per dose.
  • B a B/Beijing/184/93- like strain, 15 g HA per dose.
It was also determined that the following viruses are suitable vaccine strains:
  • The high yield reassortant viruses IVR-108 and RESVIR-13 are A/Sydney/5/97 (H3N2)-like strains
  • The high yield reassortant virus X-127 is accepted as an A/Beijing/262/95 (H1N1)-like strain
  • B/Harbin/7/94 is accepted as a B/Beijing/184/93-like strain

This article was published in Communicable Diseases Intelligence Volume 22, No 12, 26 November 1998.

Communicable Diseases Intelligence subscriptions

Sign-up to email updates: Subscribe Now

This issue - Vol 22, No 12, 26 November 1998